Keywords
nephroprotection
cardiovascular risk
N-terminal pro-brain natriuretic peptide
How to Cite
Abstract
In press
This study was dedicated to evaluating the impact of the Sodium-GLucose coTransporter 2 (SGLT2) inhibitor dapagliflozin on renal and cardiometabolic parameters in patients with a combination of arterial hypertension (AH) and type 2 diabetes mellitus (T2DM). Over the course of 12 months, 77 patients with confirmed AH and T2DM received dapagliflozin at a daily dose of 10 mg as part of their combination therapy, which also included standard antihypertensive medications and statins. A comprehensive clinical and instrumental examination was conducted before and after treatment, which included anthropometric measurements (body mass index), laboratory evaluation of glycemic and lipid profiles, renal biomarkers (cystatin C, β2-microglobulin, Neutrophil Gelatinase-Associated Lipocalin (NGAL), and estimated glomerular filtration rate), and cardiac function markers such as N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP). Echocardiographic assessment focused on evaluating changes in both structural and functional characteristics of the heart, with particular emphasis on left ventricular systolic and diastolic performance. After 12 months of dapagliflozin treatment, there was a statistically significant improvement in glycemic control and lipid metabolism, along with a reduction in body mass index. Furthermore, favorable changes were observed in renal function parameters, suggesting nephroprotective effects. A substantial decrease in NT-proBNP levels was also noted, reflecting reduced myocardial stress. Echocardiographic findings confirmed reverse remodeling of the left ventricle and improved cardiac performance. These results support the use of dapagliflozin as a multifactorial agent that exerts metabolic, renal, and cardiovascular benefits in patients with combined AH and T2DM, indicating its value in integrated cardiometabolic care.
Keywords: dapagliflozin, nephroprotection, cardiovascular risk, N-terminal pro-brain natriuretic peptide.
References
Teck J. Diabetes-Associated Comorbidities. Prim Care. 2022;49(2):275-86. DOI: 10.1016/j.pop.2021.11.004. PMID: 35595482.
Yen FS, Wei JC, Chiu LT, Hsu CC, Hwu CM. Diabetes, hypertension, and cardiovascular disease development. J Transl Med. 2022;20(1):9. DOI: 10.1186/s12967-021-03217-2. PMID: 34980154.
Hung MJ. Diabetes, Hypertension and Cardiovascular Disease: Clinical Insights, Mechanisms and Pharmacotherapies. Medicina (Kaunas). 2024;60(4):566. DOI: 10.3390/medicina60040566. PMID: 38674212.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-86. DOI: 10.2337/dci22-0034. PMID: 36148880.
KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;101(5):S1-127. DOI: 10.1016/j.kint.2022.01.002.
Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28(9):1956-64. DOI: 10.1038/s41591-022-01971-4. PMID: 36030328.
Leiter LA, McGuire DK, Wilding J, Averkov O, Budaj A, Parkhomenko A, et al. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial. JAMA Cardiol. 2023;8(5):503-9. DOI: 10.1001/jamacardio.2023.0019. PMID: 36857035.
Wheeler DC, Toto RD, Stefansson BV, Jongs N, Chertow GM, Greene T, et al.; DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215-24. DOI: 10.1016/j.kint.2021.03.033. PMID: 33878338.
American Diabetes Association. Standards of Medical Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl.1):S1-4. DOI: 10.2337/dc23-Sint. PMID: 36507647.
Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. DOI: 10.1093/eurheartj/ehad192. Erratum in: Eur Heart J. 2023;44(48):5060. DOI: 10.1093/eurheartj/ehad774. Erratum in: Eur Heart J. 2024;45(7):518. DOI: 10.1093/eurheartj/ehad857. PMID: 37622663.
Rishko OA, Derbak MA, Ihnatko YY, Dankanych YЕ, Bletskan MM, Krasnova AA, et al. The clinical experience of the effective use of dapagliflozin in comorbid cardiac patients with concomitant type 2 diabetes mellitus and arterial hypertension on the background of overweight in outpatient setting. Wiad Lek. 2022;75(10):2397-401. DOI: 10.36740/WLek202210114. PMID: 36472267.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-57. DOI: 10.1056/NEJMoa1812389. PMID: 30415602.
Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-46. DOI: 10.1056/NEJMoa2024816. PMID: 32970396.
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. DOI: 10.1056/NEJMoa1911303. PMID: 31535829.
Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108-17. DOI: 10.1007/s00125-018-4670-7. PMID: 30132036.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.